Elanco Animal Health (ELAN) presents a deeply negative liquidation posture as of March 31, 2026. Under the liquidation lens, haircutted assets fall well short of face-value liabilities, with equity recovery negative by a wide margin. Total reported assets are $13.2B; after applying standard recovery haircuts, realizable value is materially lower. Cash of $428M recovers at par. Accounts receivable of $1.1B recovers at roughly $1.0B (90-95%). Inventory of $1.7B net (gross $1.8B, LIFO reserve $74M) recovers at approximately $1.0B at 60%. PP&E net of $1.4B recovers at $700M-$980M (50-70%). Goodwill of $4.7B and other intangibles of $3.2B recover at zero. Prepaid and other current assets of $285M are largely non-recoverable in liquidation. Total haircutted asset recovery approximates $4.0B-$4.5B. Against this, face-value liabilities total $6.7B: current liabilities of $1.7B (including $817M in other current liabilities, of which $400M is the sales rebates/discounts accrual, and $73M current portion of LTD/finance lease); long-term debt and finance lease obligations of $3.9B; deferred tax liabilities of $366M; other noncurrent liabilities of $467M; plus the $309M liability for sale of future revenue (Blackstone PSA, discussed in MD&A and Note 10, not separately broken out from other noncurrent liabilities in TAG_CONTEXT). The implied shortfall to equity holders exceeds $2B-$3B on a liquidation basis, consistent with MFFAIS's reported CLV of negative $1.2B and LLV of negative $150M. The dominant drivers of the shortfall are $7.9B in zero-recovery intangibles (goodwill plus other intangibles), the $3.7B senior debt load, and the $309M royalty monetization liability accruing imputed interest at 18.3%. Since the prior filing (December 31, 2025 10-K), no material change in the capital structure occurred during Q1 2026; however, the AHV acquisition closed April 30, 2026 for $70M upfront plus up to $140M contingent and $100M deferred guaranteed payments, adding liability commitments not yet on the Q1 balance sheet. The 2025 Restructuring Plan ($155M charged in Q4 2025, $14M in Q1 2026) is converting some PP&E to wind-down costs but does not materially shift the liquidation calculus. Derivative liability exposure increased from $184M (Dec 2025) to $180M current (Mar 2026), primarily interest rate swaps marked to market. Operating cash flow remains thin at $13M for the quarter.
▼ Community Notes